Takeda Oncology presented efficacy and safety data from the phase III PhALLCON trial studying Iclusig (ponatinib) in adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia during a virtual American Society of Clinical Oncology’s Plenary Series Program Feb. 15.
The updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 1.2023 recognize Agendia Inc.’s MammaPrint UltraLow Risk result and its proven impact on patient care.
In a phase II, single-arm study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, patients with resectable non-small cell lung cancer who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
Interim data from a phase II study produced positive safety and efficacy data for bel-sar (belzupacap sarotalocan) for the first-line treatment of patients with early-stage choroidal melanoma. With an average of nine months of follow up, the interim data shows the evaluation of two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal route of administration.
In a study published in Cancer Immunology Research, researchers at Moffitt Cancer Center, led by Amer A. Beg, show how stimulating dendritic cells through the CD40 and interferon β pathways produces strong T-cell activity against tumors and works in conjunction with immune checkpoint inhibitors to produce even stronger responses.
The New York Proton Center has initiated three FLASH radiation therapy mouse model studies that will examine the use of FLASH RT to improve treatment of lung, pelvic, and abdominal tumors. NYPC researchers are conducting the studies in partnership with oncologists at Memorial Sloan Kettering Cancer Center, Montefiore Einstein Cancer Center, and Mount Sinai Health System.
Researchers at MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer, highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors. The study was published in Cancer Cell.
A study by New York University researchers, published this week in the journal Proceedings of the National Academy of Sciences, explains why cancers not only stop responding to kinase inhibitors but come back stronger, a finding that could inform which drugs oncologists use as a first-line treatment.
The phase III NRG-GY018 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival for the treatment of patients with stage 3-4 or recurrent endometrial carcinoma regardless of mismatch repair status.
